Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says

MT Newswires Live08-04 23:49

Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercial traction while multiple pipeline data readouts remain on track for H2 2026, RBC Capital said in a Monday note.

According to the note, Casgevy's Q2 revenue rose to $76 million on broader market adoption, though the therapy remains unprofitable as RBC awaits progress in the company's in vivo gene-editing programs.

RBC said H2 2026 is expected to bring several pipeline readouts, including the phase Ia data for the ANG3 program, the phase II results from the factor XI siRNA collaboration with Sirius Therapeutics, and phase I updates for the company's allogeneic CAR-T programs.

Meanwhile, RBC analysts said Crispr ended the quarter with about $2.4 billion in cash and lower-than-expected operating expenses but remains cautious on its ex vivo gene-editing programs as Casgevy has yet to reach profitability despite pipeline diversification into siRNA.

RBC maintained its sector perform rating on the stock with a $50 price target.

Crispr Therapeutics shares were up more than 3% in Tuesday trading.

Price: 51.33, Change: +1.76, Percent Change: +3.55

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656555065?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 23:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656555065","market":"sh","top_or_hot":-1,"title":"Crispr Therapeutics Posts \"Quiet\" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CRSP\">Crispr</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercial traction while multiple pipeline data readouts remain on track for H2 2026, RBC Capital said in a Monday note.</p><p>According to the note, Casgevy's Q2 revenue rose to $76 million on broader market adoption, though the therapy remains unprofitable as RBC awaits progress in the company's in vivo gene-editing programs.</p><p>RBC said H2 2026 is expected to bring several pipeline readouts, including the phase Ia data for the ANG3 program, the phase II results from the factor XI siRNA collaboration with Sirius Therapeutics, and phase I updates for the company's allogeneic CAR-T programs.</p><p>Meanwhile, RBC analysts said Crispr ended the quarter with about $2.4 billion in cash and lower-than-expected operating expenses but remains cautious on its ex vivo gene-editing programs as Casgevy has yet to reach profitability despite pipeline diversification into siRNA.</p><p>RBC maintained its sector perform rating on the stock with a $50 price target.</p><p>Crispr Therapeutics shares were up more than 3% in Tuesday trading.</p><p>Price: 51.33, Change: +1.76, Percent Change: +3.55</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crispr Therapeutics Posts \"Quiet\" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrispr Therapeutics Posts \"Quiet\" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-04 23:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CRSP\">Crispr</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercial traction while multiple pipeline data readouts remain on track for H2 2026, RBC Capital said in a Monday note.</p><p>According to the note, Casgevy's Q2 revenue rose to $76 million on broader market adoption, though the therapy remains unprofitable as RBC awaits progress in the company's in vivo gene-editing programs.</p><p>RBC said H2 2026 is expected to bring several pipeline readouts, including the phase Ia data for the ANG3 program, the phase II results from the factor XI siRNA collaboration with Sirius Therapeutics, and phase I updates for the company's allogeneic CAR-T programs.</p><p>Meanwhile, RBC analysts said Crispr ended the quarter with about $2.4 billion in cash and lower-than-expected operating expenses but remains cautious on its ex vivo gene-editing programs as Casgevy has yet to reach profitability despite pipeline diversification into siRNA.</p><p>RBC maintained its sector perform rating on the stock with a $50 price target.</p><p>Crispr Therapeutics shares were up more than 3% in Tuesday trading.</p><p>Price: 51.33, Change: +1.76, Percent Change: +3.55</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656555065","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656555065","pubTimestamp":1785858594,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Crispr Therapeutics  reported a relatively quiet Q2, with Casgevy continuing to gain commercial traction while multiple pipeline data readouts remain on track for H2 2026, RBC Capital said in a Monday note.According to the note, Casgevy's Q2 revenue rose to $76 million on broader market adoption, though the therapy remains unprofitable as RBC awaits progress in the company's in vivo gene-editing programs.RBC said H2 2026 is expected to bring several pipeline readouts, including the phase Ia data for the ANG3 program, the phase II results from the factor XI siRNA collaboration with Sirius Therapeutics, and phase I updates for the company's allogeneic CAR-T programs.Meanwhile, RBC analysts said Crispr ended the quarter with about $2.4 billion in cash and lower-than-expected operating expenses but remains cautious on its ex vivo gene-editing programs as Casgevy has yet to reach profitability despite pipeline diversification into siRNA.RBC maintained its sector perform rating on the stock ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRSP":"CRISPR Therapeutics AG","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4611":"AI医疗","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","ARKG":"ARK Genomic Revolution ETF","LENZ":"Therapeutics","BK4007":"制药","BK4588":"碎股","BK4539":"次新股"},"translate_title":"加拿大皇家银行表示，随着 Casgevy 的进展和 SiRNA 数据即将公布，Crispr Therapeutics 的季度“平静”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1,"LENZ":1.5,"ARKG":0.6},"content_text":"Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercial traction while multiple pipeline data readouts remain on track for H2 2026, RBC Capital said in a Monday note.According to the note, Casgevy's Q2 revenue rose to $76 million on broader market adoption, though the therapy remains unprofitable as RBC awaits progress in the company's in vivo gene-editing programs.RBC said H2 2026 is expected to bring several pipeline readouts, including the phase Ia data for the ANG3 program, the phase II results from the factor XI siRNA collaboration with Sirius Therapeutics, and phase I updates for the company's allogeneic CAR-T programs.Meanwhile, RBC analysts said Crispr ended the quarter with about $2.4 billion in cash and lower-than-expected operating expenses but remains cautious on its ex vivo gene-editing programs as Casgevy has yet to reach profitability despite pipeline diversification into siRNA.RBC maintained its sector perform rating on the stock with a $50 price target.Crispr Therapeutics shares were up more than 3% in Tuesday trading.Price: 51.33, Change: +1.76, Percent Change: +3.55","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656555065","isCrawlerRequest":true}